Готові списки джерел за темами / Post acute covid 19 syndrome

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Post acute covid 19 syndrome"

Автор: Grafiati

Опубліковано: 29 березня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Post acute covid 19 syndrome".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Post acute covid 19 syndrome"

Nalbandian, Ani, Kartik Sehgal, Aakriti Gupta, Mahesh V. Madhavan, Claire McGroder, Jacob S. Stevens, Joshua R. Cook, et al. "Post-acute COVID-19 syndrome." Nature Medicine 27, no. 4 (March 22, 2021): 601–15. http://dx.doi.org/10.1038/s41591-021-01283-z.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ali Shah, Syed Zulfiquar, Ikram Din Ujjan, and Naveed Aslam Lashari. "Post-Acute Covid-19 Syndrome." Pakistan Journal of Medical and Health Sciences 15, no. 5 (May 30, 2021): 891–92. http://dx.doi.org/10.53350/pjmhs21155891.

Повний текст джерела

Анотація:

The coronaviruses (CoVs) belongs to the subgroup Orthocoronavirinae in the family Coronaviridae, Order Nidovirales.1 During 2002, the China reports first outbreak of SARS quickly spread worldwide, leads to approximately 11% fatality rate while during 2012;2 Middle East Respiratory Syndrome (MERS) originates in Saudi Arabia followed by its spread worldwide with 37% mortality.3 During December 2019, an pneumonia of unknown etiology has been detected in vast majority of patients resides in Wuhan City, Central China and Hubei Province.4 The Genomic research has been identified that this pneumonia considered as coronavirus disease 2019 caused by novel corona virus (CoV) labeled as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), formerly called as 2019-novel coronavirus (2019-nCoV).5 The screening and management strategies are not sufficient to end the battled against COVID-19.6 The survivors face various long terms symptoms produced by COVID-19 which are still the matter of debate.7 The literature reported 50-90% individuals have persistent symptoms and considered as long-haulers but due to confounders as gender, age, race, duration and severity of infection, short term study period and follow ups the results are hampered and limited.8

Стилі APA, Harvard, Vancouver, ISO та ін.

Montani, David, Laurent Savale, Nicolas Noel, Olivier Meyrignac, Romain Colle, Matthieu Gasnier, Emmanuelle Corruble, et al. "Post-acute COVID-19 syndrome." European Respiratory Review 31, no. 163 (March 9, 2022): 210185. http://dx.doi.org/10.1183/16000617.0185-2021.

Повний текст джерела

Анотація:

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic that has resulted in millions of deaths and a major strain on health systems worldwide. Medical treatments for COVID-19 (anticoagulants, corticosteroids, anti-inflammatory drugs, oxygenation therapy and ventilation) and vaccination have improved patient outcomes. The majority of patients will recover spontaneously or after acute-phase management, but clinicians are now faced with long-term complications of COVID-19 including a large variety of symptoms, defined as “post-acute COVID-19 syndrome”. Most studies have focused on patients hospitalised for severe COVID-19, but acute COVID-19 syndrome is not restricted to these patients and exists in outpatients. Given the diversity of symptoms and the high prevalence of persistent symptoms, the management of these patients requires a multidisciplinary team approach, which will result in the consumption of large amounts of health resources in the coming months. In this review, we discuss the presentation, prevalence, pathophysiology and evolution of respiratory complications and other organ-related injuries associated with post-acute COVID-19 syndrome.

Стилі APA, Harvard, Vancouver, ISO та ін.

Murga Gandasegui, I. "About post-acute COVID-19." ANALES RANM 141, no. 141(03) (2024): 199–200. https://doi.org/10.32440/ar.2024.141.03.rev01.

Повний текст джерела

Анотація:

The SARS-CoV-2 pandemic has caused great consequences for our healthcare systems. Throughout the European Union (EU) 17 million people have been affected by Long COVID in the first two years of the pandemic and this number continues to increase. Physicians must take this situation into account in their clinical practice, where they will treat patients with isolated persistent symptoms and others with multisystemic repercussions, with a predominance of disabling physical and mental fatigue for which no explanation can be found after the countless tests performed. An aspect to be assessed is its similarity with Post-viral Fatigue Syndrome/Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (ICD-11: 8E49). All these elements must be addressed by specialized units given their socio-health complexity.

Стилі APA, Harvard, Vancouver, ISO та ін.

O’Keefe, Louise C. "Post-Acute COVID 19 Syndrome, ‘Long COVID’." Workplace Health & Safety 71, no. 5 (April 27, 2023): 263. http://dx.doi.org/10.1177/21650799231164605.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Cha, Jae Myung. "Post-COVID-19 Syndrome." Korean Journal of Medicine 97, no. 5 (October 1, 2022): 284–91. http://dx.doi.org/10.3904/kjm.2022.97.5.284.

Повний текст джерела

Анотація:

Although acute COVID-19 usually lasts for 12 weeks from the onset of symptoms, some patients experience variable persistent symptoms. Post-COVID-19 syndrome is defined as persistent symptoms and/or long-term complications that appear during or after COVID-19, persist for more than 12 weeks, and cannot be explained by an alternative diagnosis. The common symptoms of post-COVID-19 syndrome include general, pulmonary, hematological, cardiovascular, neuropsychiatric, renal, endocrine, gastroenterological, and dermatological symptoms. As the natural course and pathophysiology of COVID-19 are not yet clear, close monitoring is needed for various sequelae in multiple organs that occur in post-COVID-19 syndrome. In particular, patients who have been hospitalized in the intensive care unit or who have recovered from severe COVID-19 require close monitoring for the development of post-COVID-19 syndrome. Multidisciplinary collaboration is essential to provide integrated outpatient care for patients with post-COVID-19 syndrome.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kaushik, Arun, Kishalay Datta, Anita Rawat, and Ashar Khan. "Post Covid Acute Necrotizing Pancreatitis." Indian Journal of Emergency Medicine 7, no. 1 (March 15, 2021): 35–38. http://dx.doi.org/10.21088/ijem.2395.311x.7121.6.

Повний текст джерела

Анотація:

The Coronavirus Pandemic began in China in December 2019. In a short time, this pandemic spread globally. World has been challenged by SARS COV-2, a new virus causing pneumonia and acute respiratory distress syndrome. There is lack of literature implicating COVID-19 in Pancreatitis, yet virus is generally understood to be a cause of pancreatitis in children. We present a case of previously well 12-year-old girl who presented to emergency department with a chief complain of abdominal pain, anorexia and bilious vomiting. She was diagnosed with acute pancreatitis with an abnormal lipase, ultrasound and computed tomography and was found to be COVID-19 positive by polymerase chain reaction. Our case suggest that in current pandemic, consideration for SARS COV2 testing in children with gastrointestinal symptoms and pancreatitis may be considered. Additionally, this case highlights the need for appropriate personal protective equipment for providers, even when COVID is not initially on the differential.

Стилі APA, Harvard, Vancouver, ISO та ін.

Asfandiyarova, N. S. "Post-COVID-19 syndrome." Clinical Medicine (Russian Journal) 99, no. 7-8 (January 4, 2022): 429–35. http://dx.doi.org/10.30629/0023-2149-2021-99-7-8-429-435.

Повний текст джерела

Анотація:

The disease caused by new coronavirus infection (COVID-19) is a global problem not only because of its wide spread occurrance, but also due to the high incidence of post-COVID syndrome. The literature review presents the results of numerous observations of patients, who undergone COVID-19. The most common symptoms are: general weakness, impaired cognitive functions, memory loss, depression, anosmia, dysgeusia, shortness of breath, cough, chest pain, abdominal pain, anorexia, nausea, vomiting, diarrhea, less often — alopecia, skin rashes, etc. The most frequent symptoms of the post-COVID syndrome are described; the reasons and risk factors for its development are analyzed. The lack of views sameness on the term “postCOVID syndrome” makes it diffi cult to evaluate the frequency of certain symptoms development. Variants of the post-COVID syndrome are considered. It is proposed to distinguish between the post-COVID syndrome, developed after acute COVID-19 that lasts up to 12 weeks, and a prolonged variant of post-COVID clinical symptoms that last longer than 12 weeks, which should be distinguished from lingering COVID-19, its complications, and the consequences of intensive care. The questions of prognosis, diagnostics, and treatment of post-COVID syndrome are discussed.

Стилі APA, Harvard, Vancouver, ISO та ін.

Al-Jahdhami, Issa, Khalid Al-Naamani, and Adhra Al-Mawali. "The Post-acute COVID-19 Syndrome (Long COVID)." Oman Medical Journal 36, no. 1 (January 15, 2021): e220-e220. http://dx.doi.org/10.5001/omj.2021.91.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Chiappelli, Francesco. "Post acute CoViD-19 syndrome (PACS) - Long CoViD." Bioinformation 18, no. 10 (October 31, 2022): 908–11. http://dx.doi.org/10.6026/97320630018908.

Повний текст джерела

Анотація:

Patients sero-positive for the Systemic Acute Respiratory Syndrome Corona virus2 (SARS-CoV2) virus develop the Corona Virus Disease 2019 (CoViD-19). CoViD-19 may be asymptomatic in some individuals, proffer mild symptoms in other patients, and can be a serious and even lethal disease in a sub-group of the population. The variables that determine the severity of CoViD-19 have not been fully characterized. What is clear is that the patients who survive CoViD-19 return to a state of sero-negativity for SARS-CoV2 generally within 3-5 weeks. However, several cases of repeated infection have been reported, and a large proportion of CoViD-19-recovered patients manifest multi-system and multi-organ symptomatic pathologies several weeks-to-months after resuming sero-negativity for SARS-CoV2. This new pathological condition, originally termed Long Covid, is now recognized as the Post Acute CoViD-19 Syndrome (PACS). The original principal clusters of signs and symptoms of PACS: likelihood of relapse and reinfection, physical fatigue and cognitive slowdown, may actually be broadened to include immune deregulation, cardiovascular disease and coagulation abnormalities. The development and evaluation of new and improved clinical interventions for PACS are critical and timely.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Post acute covid 19 syndrome"

Vandersteen, Clair. "COVID long olfactif et maladie d'Alzheimer : mécanismes physiopathologiques partagés, défis diagnostiques et nouvelles approches thérapeutiques." Electronic Thesis or Diss., Université Côte d'Azur, 2024. https://theses.hal.science/tel-05000086.

Повний текст джерела

Анотація:

Cette thèse a étudié les connexions potentielles entre le COVID long (CL) et la maladie d'Alzheimer (MA) étant donné les facteurs de risque et processus physiopathologiques partagés existants entre ces deux pathologies. Nous nous sommes concentrés sur les patients atteints de Dysosmies post COVID-19 persistantes (DPCP) s'intégrant donc dans un CL olfactif. Les études radiologiques et neurocognitives soutiennent des modifications cérébrales communes identifiable dans le CL et la MA, notamment l'hypométabolisme et les changements structurels dans les zones liées à l'olfaction et à la mémoire. Cette thèse s'articulera uniquement autour des 9 travaux distincts qui la constituent.Une revue de littérature exhaustive initiale associée à un consensus d'experts internationaux nous a permis de mettre en évidence les chevauchements cliniques potentiels entre les symptômes du CL et ceux ciblés par les biomarqueurs spécifiques des formes préclinique de MA, soulignant les difficultés prévisibles de son dépistage précoce. Nous suggérons ainsi de faire preuve de prudence dans l'utilisation des outils modernes de dépistage d'une forme préclinique de MA pour les patients CL en raison du risque de biomarqueurs cliniques faussement positifs. Nos travaux sur l'un de ces biomarqueurs (olfaction) révèlent que les DPCP présentent une signature centrale, distincte des atteintes olfactives post-virales périphériques dites classiques. Nous avons aussi observé un déficit de la mémoire sémantique chez 20 % des patients présentant une DPCP, en particulier chez les individus les plus jeunes (19-39 ans). Par ailleurs, les patients présentant une DPCP montraient une forme de résistance aux méthodes de rééducation olfactives conventionnelles. De ce fait, nous avons développé un nouveau protocole de rééducation olfactive basé sur une approche cognitive et visuo-olfactive, (MaMadeleine™), montrant des résultats prometteurs sur la DPCP et la mémoire sémantique. De plus, nous avons mis en parallèle le rôle potentiel de la charge allostatique et du stress post traumatique dans la pathogénie du CL et de la MA, suggérant une interaction complexe entre les facteurs environnementaux, la dysrégulation physiologique et le déclin cognitif. Enfin, nous avons observé, chez les patients présentant une DPCP, des altérations de la motricité fine, en particulier dans la cinétique de l'écriture manuscrite, partageant certaines similitudes avec celles rapportées chez les patients atteints de MA précoce ou de troubles cognitifs mineurs. Nous recommandons ainsi un suivi à long terme des patients CL pour évaluer les risques de genèse de potentiels troubles neurodégénératifs à long terme. Ces résultats soulèvent parallèlement certaines préoccupations concernant la poursuite de l'utilisation d'évaluations psychométriques automatisées distancielles, telles qu'une olfactométrie automatisée ou l'analyse cinématique de l'écriture manuscrite, pour le dépistage précoce d'une MA chez les patients CL.Cette thèse contribue à une meilleure compréhension des implications neurologiques à long terme du CL et de sa relation potentielle avec les processus neurodégénératifs, soulignant l'importance de poursuivre la recherche cognitive et neurosensorielle chez cette population émergente de patients, désormais endémique
This thesis investigated the potential connections between Post-Acute COVID-19 Syndrome (PACS) and early stages of Alzheimer's Disease (AD) given shared risk factors and pathophysiological processes, focusing on olfactory dysfunction (OD) patients. Neurocognitive and neuroimaging studies reveal overlapping patterns of brain alterations in PACS and early AD, including hypometabolism and structural changes in olfactory and memory-related areas. This thesis will focus exclusively on the nine distinct works that constitute it.An initial comprehensive literature review and international expert consensus helped us to highlight the potential clinical overlaps between PACS symptoms and early AD stages, underlining predictable early AD stage screening difficulties using modern remote digital assessments. We suggested caution in using modern early AD screening tools for PACS patients due to symptom and biomarker overlaps. Our findings concerning one of these biomarkers (olfaction) reveal that this specific OD exhibits a central signature, distinct from peripheral post-viral olfactory impairments. We also reported an impairment of semantic memory in 20% of PACS-related OD patients, particularly in younger individuals (19-39 years). PACS-related OD patients showed quite a resistance to conventional olfactory training (OT) methods, necessitating cognitive and visuo-olfactory approaches. We developed a novel OT protocol, MaMadeleine™, showing promising results in improving olfactory function and semantic memory. Additionally, we highlighted the potential role of allostatic load and posttraumatic stress in PACS and AD pathogenesis, suggesting a complex interplay between environmental factors, physiological dysregulation, and cognitive decline. Finally, we reported fine motor impairments in PACS-related OD patients, particularly in handwriting kinetics, sharing some similarities with those reported in early AD or Mild Cognitive Impairment patients. We thus recommended long-term monitoring of PACS patients to assess neurodegenerative disorder genesis risks. These findings raise concerns about using certain remote automated psychometric assessments, such as olfactory tests and kinetic handwriting analysis, for early AD screening in PACS patients.This comprehensive work contributes to understanding PACS's long-term neurological implications and its potential relationship with neurodegenerative processes, emphasizing the importance of continued research and tailored clinical approaches for this emerging patient population

Стилі APA, Harvard, Vancouver, ISO та ін.

Phan, Ngoc Minh Hien. "Perusing peripatetic pathogenic viruses: Hepatitis B virus and severe acute respiratory syndrome coronavirus 2." Thesis, Queensland University of Technology, 2021. https://eprints.qut.edu.au/226107/1/Ngoc%20Minh%20Hien_Phan_Thesis.pdf.

Повний текст джерела

Анотація:

This project characterised the genetic diversity of hepatitis B virus (HBV) and SARS-CoV-2, which reflects viral evolution, and drives transmission, viral pathogenesis, and clinical outcomes. Genomes and coding genes of these viruses were analysed using next-generation sequencing, bioinformatic tools and publicly available viral sequences. HBV nucleotide diversity was identified amongst HBV sequences from Australian and non-Australian blood donors. In addition, the frequency of HBV mutants circulating in Southeast Asia, Australia and New Zealand was identified. Europe and East Asia were shown as major sources of Australian SARS-CoV-2 during the beginning of the pandemic in 2020.

Стилі APA, Harvard, Vancouver, ISO та ін.

Habas, Khaled S. A., C. Nganwuchu, F. Shahzad, Rajendran C. Gopalan, M. Haque, Sayeeda Rahman, A. A. Majumder, and Md Talat Nasim. "Resolution of coronavirus disease 2019 (COVID-19)." 2007. http://hdl.handle.net/10454/17989.

Повний текст джерела

Анотація:

Yes
Introduction. Coronavirus disease 2019 (COVID-19) was first detected in China in December, 2019, and declared as a pandemic by the World Health Organization (WHO) on March 11, 2020. The current management of COVID-19 is based generally on supportive therapy and treatment to prevent respiratory failure. The effective option of antiviral therapy and vaccination are currently under evaluation and development. Areas covered. A literature search was performed using PubMed between December 1, 2019–June 23, 2020. This review highlights the current state of knowledge on the viral replication and pathogenicity, diagnostic and therapeutic strategies, and management of COVID-19. This review will be of interest to scientists and clinicians and make a significant contribution toward development of vaccines and targeted therapies to contain the pandemic. Expert Opinion. The exit strategy for a path back to normal life is required, which should involve a multi-prong effort toward development of new treatment and a successful vaccine to protect public health worldwide and prevent future COVID-19 outbreaks. Therefore, the bench to bedside translational research as well as reverse translational works focusing bedside to bench is very important and would provide the foundation for the development of targeted drugs and vaccines for COVID-19 infections.
Research carried out at TN laboratories are funded by the GrowMedtech, The Royal Society and University of Bradford. KH is supported by a project grant by the GrowMedtech awarded to TN. CW is funded by a Ph.D studentship.
Full text of this article will be released for public view at the end of the publisher embargo on 5 Aug 2021.

Стилі APA, Harvard, Vancouver, ISO та ін.

Habas, Khaled S. A., Chinyere C. Nganwuchu, F. Shahzad, Rajendran C. Gopalan, M. Haque, Sayeeda Rahman, A. A. Majumder, and Md Talat Nasim. "Resolution of coronavirus disease 2019 (COVID-19)." 2020. http://hdl.handle.net/10454/17989.

Повний текст джерела

Анотація:

Стилі APA, Harvard, Vancouver, ISO та ін.

Crispim, Bianca Félix de Oliveira. "Medidas epidemiológicas e análises laboratoriais para o estudo do SARS-CoV-2." Master's thesis, 2021. http://hdl.handle.net/10284/10262.

Повний текст джерела

Анотація:

A COVID-19 se manifesta principalmente como uma infecção respiratória. No entanto, um grande número de estudos mostra características de doença ubíqua com repercussões nos sistemas cardiovascular, respiratório, gastrointestinal, neurológico, hematopoiético e imunológico. Estudos conduzidos em vários centros de pesquisa na China, Europa e Estados Unidos da América indicam que os resultados laboratoriais podem fornecer à equipe clínica muitos marcadores preditivos úteis. O efeito no sistema hematopoiético e na hemostasia é evidenciado por alterações significativas no número de linfócitos, granulócitos e plaquetas, bem como alterações no processo de coagulação. Esses parâmetros podem ser monitorados e ter um efeito preditivo no curso da doença e podem ajudar a identificar pacientes que precisam de cuidados intensivos. Em resumo, a COVID19 apresenta alterações significativas no sistema hematopoiético e está frequentemente associada a um estado de hipercoagulabilidade. A avaliação cuidadosa dos índices laboratoriais no início da doença e durante a doença pode ajudar os médicos a formular um tratamento adequado à situação, além de permitir cuidados especiais para os pacientes mais necessitados.
COVID-19 manifests itself mainly as a respiratory infection. However, many studies show characteristics of an ubiquitous disease with repercussions on the cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic and immunological systems. Studies conducted at several research centers in China, Europe and the United States of America indicate that laboratory results can provide the clinical team with many useful predictive markers. The effect on the hematopoietic system and hemostasis is evidenced by significant changes in the number of lymphocytes, granulocytes, and platelets, as well as changes in the coagulation process. These parameters can be monitored and have a predictive effect on the course of the disease and can help to identify patients who need intensive care. In summary, COVID-19 has significant changes in the hematopoietic system and is often associated with a state of hypercoagulability. Careful evaluation of laboratory indexes at the beginning of the disease and during the disease can help doctors to formulate an appropriate treatment for the situation, in addition to allowing special care for the neediest patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

Parreiras, Susana Catapirra Magessi. "Rationally Designed Antiviral Proteins Targeting SARS-CoV-2." Master's thesis, 2022. http://hdl.handle.net/10362/135543.

Повний текст джерела

Анотація:

O SARS-CoV-2 é o vírus responsável pela atual pandemia COVID-19, que causou >400 mi-lhões de infeções e >5 milhões de mortes, a datar de Fevereiro de 2022. Apesar dos esforços de vacinação, continua a ser urgente desenvolver estratégias para controlar a infeção e tratar as pes-soas infetadas que apresentam sintomas. O SARS-CoV-2 é um vírus de RNA de sentido positivo que pertence à família Coronaviridae. A sua estrutura externa é esférica, sendo encapsulado por uma membrana viral e, de forma a infetar a célula hospedeira, precisa de fundir a sua membrana com a membrana desta célula. Uma das proteínas que está ligada à membrana viral do vírus é a proteína spike (S), que é composta por duas subunidades: S1, que contém um domínio de ligação ao recetor (RBD) respon-sável pela ligação ao recetor da célula hospedeira, e S2, que facilita a fusão membranar entre as membranas do vírus e da célula do hospedeiro. Assim, esta proteína é a principal responsável pela capacidade do vírus de entrar nas células hospedeiras, tornando-a num dos alvos terapêuticos mais promissores dos coronavírus. O objetivo deste trabalho era conceber e produzir proteínas antivirais que pudessem impedir a interação entre as duas proteínas e, assim, bloquear a infeção. Estas proteínas são concebidas para se ligarem à região do RBD e bloquear a sua interação com o recetor hospedeiro, a enzima conversora da angiotensina-2 (ACE2). Numa primeira etapa, várias proteínas antivirais foram computacionalmente concebidas com o programa Rosetta, com base nas interações entre a ACE2 e o domínio de ligação ao recetor da proteína S. Posteriormente, realizaram-se simulações de dinâmica molecular (MD) de três candida-tos, tanto livres em solução como em complexo com o RBD, a fim de testar a sua interação com esta proteína. Seguiu-se uma validação experimental que começou com a expressão e purificação dos três candidatos. Após a obtenção de frações puras, a estrutura secundária e a estabilidade tér-mica destas proteínas foram testadas, respetivamente, por espetropolarimetria de dicroísmo circular no UV distante e fluorimetria de varrimento diferencial. A fim de avaliar a afinidade de cada candida-to para com o RBD, foi utilizada a ressonância plasmónica de superfície. Finalmente, foram realiza-dos ensaios de neutralização para estudar a capacidade destas proteínas se ligarem ao RBD. Os resultados experimentais mostram que uma das proteínas concebidas representa uma estratégia terapêutica promissora que será ainda melhorada no futuro.
SARS-CoV-2 is the virus responsible for the current COVID-19 pandemic, which has caused >400 million infections and >5 million deaths, as of February 2022. Despite the vaccination efforts, it remains urgent to develop strategies to control the infection and treat patients. SARS-CoV-2 is a positive-sense RNA virus that is part of the Coronaviridae family. Its outer structure is spherical, it is encapsulated by a viral membrane and, in order to infect the host cell, it needs to fuse its membrane with the host cell membrane. One of the proteins that is attached to the viral membrane of the virus is the spike (S) protein, which is composed of two subunits: S1, containing a receptor binding domain (RBD) responsible for binding to the host cell receptor, and S2, that facilitates membrane fusion between the viral and host cell membranes. Thus, this protein is primarily responsible for the ability of the virus to enter the host cells, making it one of the most promising therapeutic targets of coronaviruses. The goal of this work was to design and produce antiviral proteins that might prevent the in-teraction between the two proteins and therefore block infection. These proteins are engineered to bind to the RBD region and block its interaction with the host receptor, the angiotensin converting enzyme-2 (ACE2). In a first step, several antiviral proteins were computationally designed with the Rosetta pro-gram, based on the interactions between ACE2 and the receptor-binding domain. Next, molecular dynamics (MD) simulations of three candidates were performed, both free in solution as well as in complex with the RBD, in order to test their interaction with the RBD. This was followed by experi-mental validation that began with the expression and purification of the three candidates. After ob-taining pure fractions, the secondary structure and thermal stability of these proteins were tested by far-UV circular dichroism spectropolarimetry and differential scanning fluorimetry, respectively. In order to assess the affinity of each candidate for the RBD, surface plasmon resonance was em-ployed. Finally, neutralization assays were performed to study the neutralization ability of the pro-teins. The experimental results show that one of the designed proteins is a promising therapeutic lead that will be further improved in the future.

Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Post acute covid 19 syndrome"

Molecular Diagnostics and Biological Safety 2021. COVID-19: Epidemiology, Diagnosis and Prophylaxis: Conference Abstracts. Central Research Institute for Epidemiology, 2021. http://dx.doi.org/10.36233/978-5-6045286-2-4.

Повний текст джерела

Анотація:

The pandemic of the new coronavirus infection has spread to more than 200 countries. To date, over 130 million people have been affected and over 2.8 million have died. COVID-19 infection has a number of specific epidemiological and clinical features. In severe cases of the disease, acute respiratory distress syndrome develops, which is often fatal. The SARS-CoV-2 virus is susceptible to mutations, which alarms the scientific community all over the world. Therefore, scientific research in the field of COVID-19, the search for new diagnostic tools, methods for nonspecific and specific prevention and treatment are central topics today.This collection contains abstracts submitted by leading experts in the field of epidemiology, clinics of infectious diseases, molecular diagnostics, young researchers and medical practitioners. Published materials contain data on the methods of molecular diagnostics of COVID-19, se-quencing of the SARS-CoV-2 genome, epidemiology of new coronavirus infection, immuno-pathogenesis of COVID-19, clinical features of infection and treatment options, as well as the study of post-infectious and post-vaccination immunity and examples of complex measures for nonspecific prevention of COVID-19.The materials of the Congress are of interest to doctors and researchers of all specialties, teachers of secondary and higher educational institutions.

Стилі APA, Harvard, Vancouver, ISO та ін.

Shoenfeld, Yehuda, and Arad Dotan. Effects and Post-COVID 19 Syndrome on Autoimmunity. Elsevier Science & Technology Books, 2023.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Shoenfeld, Yehuda, and Arad Dotan. Effects and Post-COVID 19 Syndrome on Autoimmunity. Elsevier Science & Technology, 2023.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Shisō to shite no "shingata korona uirusu-ka": Severe acute respiratory syndrome, coronavirus 2, SARS-CoV-2. Tōkyō: Kawade Shobō Shinsha, 2020.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Priori, Alberto, ed. Neurology of COVID-19. Milano University Press, 2021. http://dx.doi.org/10.54103/milanoup.57.

Повний текст джерела

Анотація:

The authors will present a comprehensive account of the neurological aspects of SARS-CoV-2 infection. The aim is to provide a practical clinical book which will serve as a guide for clinicians from all specialties involved in the management of COVID-19 patients. The authors share the extensive clinical experience gained in major hospitals in Lombardy, the first European region to face the COVID-19 emergency in 2020. All are recognized international experts in their respective fields and have been involved in the management of COVID-19 cases from the very beginning of the Italian SARS-CoV-2 outbreak. The text begins with a description of pathobiological and pathophysiological aspects related to the involvement of the nervous system, moving on to the discussion of the neurological complications observed in COVID-19 patients; these range from central to peripheral symptoms, and can occur in the acute or post-acute phases of the disease. Further topics are: neuropathology, seizures and EEG, neuroimaging, delirium, encephalomyelitis, stroke, psychopathology and psychiatry, neuropsychology and cognitive impairment, neuromuscu-lar disorders, and the impact of COVID-19 on other pre-existing neurological disorders. In addi-tion, the book will discuss the new developments in teleneurology approaches, which have been a direct response to the ongoing pandemic. Finally, the possible neurological complications of the COVID-19 vaccines and the neurological complications in children will be considered.Each chapter will present a critical review of the existing literature concerning the specific subject matter, followed by practical clinical recommendations, as well as personal considerations based on the experience gained by each author during the course of the COVID-19 pandemic. Neurology of COVID-19 will be an original and innovative reference book for clinicians of all the specialties involved in the management of patients with SARS-CoV-2 infection

Стилі APA, Harvard, Vancouver, ISO та ін.

OLSEN, Catherine. New Sars-Cov-2 More Deadly Than Covid-19: The Truth You Need to Know about Severe Acute Respiratory Syndrome Coronavirus 2. Independently Published, 2021.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Webster, Kerry. Traditional Chinese Medicine in the Treatment of Post COVID-19 Syndrome: Zhong Yi Zhen Zhi Xin Guan Chang Qi Bing Zheng. World Scientific Publishing Co Pte Ltd, 2022.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Al-Anazi, KA, WK Al-Anazi, and AM Al-Jasser. Update on COVID-19 Infections and the Promising Role of Mesenchymal Stem Cell Therapies in their Management. Heighten Science Publications Inc., 2020. http://dx.doi.org/10.29328/ebook1002.

Повний текст джерела

Анотація:

The pandemic of COVID-19 has adversely affected almost every aspect of our lives but the world health and economic sectors suffer most of the repercussions of this disease. The search for a cure for this rapidly spreading virus which is causing massive life losses around the globe requires clear understanding of the immunopathogenesis of this virus as well as the mechanisms of actions of the various therapeutic modalities that are employed in the treatment of this life-threatening viral infection. Mesenchymal stem cells have antimicrobials effects in addition to their anti-inflammatory and immunomodulatory properties. They have been utilized in the treatment of various infections and their complications both in animal models and in human clinical trials. Mesenchymal stem cells derived from certain sources and their secretory products are particularly effective in the treatment of pneumonia, sepsis, acute lung injury, and acute respiratory distress syndrome which are common complications of COVID-19 infections. The review will discuss the various aspects of COVID-19 and it will highlight the promising role of mesenchymal stem cells in treating the complications of COVID-19 infections.

Стилі APA, Harvard, Vancouver, ISO та ін.

Pandemics: The Basics. Taylor & Francis Group, 2021.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Pandemics: The Basics. Taylor & Francis Group, 2021.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Post acute covid 19 syndrome"

Adingupu, Damilola D., A. Soroush, A. Hansen, R. Twomey, and J. F. Dunn. "Reduced Cerebrovascular Oxygenation in Individuals with Post-Acute COVID-19 Syndrome (PACS) (“long COVID”)." In Advances in Experimental Medicine and Biology, 211–16. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-42003-0_33.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tarnanas, Ioannis, and Magda Tsolaki. "Making Pre-screening for Alzheimer’s Disease (AD) and Postoperative Delirium Among Post-Acute COVID-19 Syndrome (PACS) a National Priority: The Deep Neuro Study." In Advances in Experimental Medicine and Biology, 41–47. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-31982-2_4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Klimov, Vladimir V. "Allergies in COVID-19 and Post-COVID Syndrome." In Textbook of Allergen Tolerance, 267–84. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04309-3_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Li, Leon Wai, Wing Tung Percy Ho, and Pui Yu Chesney Wong. "Appropriate Care and Post-COVID-19 Syndrome." In Gaps and Actions in Health Improvement from Hong Kong and Beyond, 135–55. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-4491-0_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Vitacca, Michele, Mara Paneroni, and Nicolino Ambrosino. "Pulmonary rehabilitation in post-acute patients with COVID-19." In Pulmonary Rehabilitation, 503–10. Second edition. | Boca Raton : CRC Press, [2020] | Preceded by Pulmonary rehabilitation / Claudio F. Donner, Nicolino Ambrosino, Roger Goldstein. 2005.: CRC Press, 2020. http://dx.doi.org/10.1201/9781351015592-51.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Simova, Iana, Denislava Hristova, Hristina Tzanovska, Denis Nikolov, Diliana Iakova, Anyuta Ivanova, Maria-Magdalena Pintova, et al. "Post COVID-19 Conditions and the Cardiovascular System." In Fighting the COVID-19 Pandemic. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.99197.

Повний текст джерела

Анотація:

One out of four patients affected by COVID-19 will experience persistent (>3-4 weeks) signs and symptoms (Post COVID-19 conditions or Post-Acute Sequelae of SARS-CoV-2 – PASC) and this fact will have a major significance for the healthcare and economic systems in the upcoming years. The cardiovascular system is one of the key targets for the Post COVID-19 syndrome, given the pathogenesis of the virus and prevalence of ACE-2 receptors. According to our initial personal experience via the campaign “Life after COVID” of the Bulgarian Cardiac Institute, a substantial proportion of patients having suffered from COVID-19 develop long-term cardiovascular consequences. They could range from rhythm disorder and blood pressure variation, through impairment of myocardial mechanics and heart failure, and to acute vascular manifestations of Post COVID-19 conditions, such as acute coronary syndrome, acute pulmonary embolism, and acute limb ischemia. These cardiovascular complications require special and dedicated medical attention, and we could share our personal experience on the matter.

Стилі APA, Harvard, Vancouver, ISO та ін.

Alfalayleh, Areen. "Development of Acute COVID-19 into Post-COVID-19 syndrome." In Edited Book, 70. United Research Forum, 2022. http://dx.doi.org/10.51219/urforum.2022.areen-alfalayleh.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Barua, Ranjit, and Sudipto Datta. "Comprehensive Analysis of the COVID-19 Pandemic's Impact on the Prevalence of Acute Coronary Syndrome (ACS)." In Clinical Practice and Post-Infection Care for COVID-19 Patients, 1–16. IGI Global, 2023. http://dx.doi.org/10.4018/978-1-6684-6855-5.ch001.

Повний текст джерела

Анотація:

The COVID-19 pandemic has caused havoc in the world's healthcare systems. Acute coronary syndrome (ACS) admission rates have varied considerably during the pandemic. Even though the coronavirus disease 2019 (COVID-19) pandemic has resulted in fewer acute coronary syndromes (ACS) patients being admitted to hospitals worldwide, clinical characteristics of those patients have not yet been thoroughly examined. Investigating the incidence, clinical presentation, and outcomes of patients with ACS during the COVID-19 pandemic is the goal of the chapter.

Стилі APA, Harvard, Vancouver, ISO та ін.

de Andrade, Daniel Ciampi. "Pain and COVID-19." In Neuropathic Pain, edited by Nadine Attal and Didier Bouhassira, 87–92. Oxford University PressNew York, 2023. http://dx.doi.org/10.1093/med/9780197616345.003.0015.

Повний текст джерела

Анотація:

Abstract This chapter presents the case of a woman who complains of persistent pain in the four limbs that started after intensive care unit (ICU) discharge due to COVID-19 infection. She fulfills criteria for Guillain–Barré syndrome, but her clinical picture may have been worsened by ICU stay. This case shows that Guillain–Barré syndrome is possible after COVID-19 and may induce neuropathic pain. Other potential causes of pain after COVID-19 mainly include post-ICU neuromuscular disorders for severe cases and long COVID syndrome. These consist of a constellation of symptoms, including headache or widespread pain, fatigue, respiratory or cardiovascular problems, and sleep disorders. These symptoms, which share similarities with other post-infectious disorders, might result from residual damage from acute infection, persistent immune activation, psychological factors, or unmasking of prior comorbidities.

Стилі APA, Harvard, Vancouver, ISO та ін.

Agarwal, Monika, Prashant Kumar Bajpai, Sugandha Jauhari, and Pratyaksha Pandit. "Perspective Chapter: Epidemiology of Post-COVID Syndrome in Indian Subcontinent." In Current Topics in Post-COVID Syndromes [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.1006970.

Повний текст джерела

Анотація:

Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, also known as long-COVID (LC) or post-COVID syndrome (PCS), became a significant public health concern after the initial COVID-19 outbreaks. PCS refers to symptoms that persist beyond the weeks- and months-long acute phase of the infection. Prioritizing the management of acute instances to lower the mortality rate led to the initial neglect of cases of such extended duration, until it was discovered that many of the patients continued to experience symptoms long after they had recovered. “Long COVID” describes a group of persistent symptoms that are detectable and identified, often four weeks following the acute sickness. PCS can be diagnosed based on a patient’s history and physical results after other diagnoses have been ruled out due to the lack of a conclusive test. The complicated interplay between the virus and host factors causes COVID-19 to change from acute to post-acute sequelae. The high absolute number of COVID-19 patients and the healthcare system’s variability contribute to the varying prevalence of PCS throughout the Indian subcontinent. This chapter explores the epidemiology of post-COVID syndrome in the Indian subcontinent, focusing on its prevalence, pathogenesis, and clinical manifestations and the implications for policy health systems, society, and culture for effective PCS management.

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Post acute covid 19 syndrome"

Nicholson, J. M., A. M. Matheson, H. K. Kooner, M. J. Mcintosh, S. Svenningsen, and G. Parraga. "Unique MRI Phenotypes Help Explain Post-Acute COVID-19 Syndrome." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6785.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lee, S. X., A. Balobaid, A. Lastinger, and R. Reece. "Follow-Up of Hospitalized Adults with Post-Acute COVID-19 Syndrome." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2651.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Friha, Mariem, Hajer Racil, Mariem Chaabane, Sarra Maazaoui, Ameny Touil, Sonia Habibech, Nawel Chaouch, and Ines Moussa. "Is acute pulmonary embolism a predictor of Post COVID-19 syndrome ?" In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa2253.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

de Oliveira, Lucas Cardeal, Fernando Ribeiro Araujo, Roberto Fontella Dinatt, and Bruna Zorzo Marques. "Review of clinical manifestations, diagnosis and treatment of post-Covid-19 syndrome." In III Seven International Medical and Nursing Congress. Seven Congress, 2024. http://dx.doi.org/10.56238/iiicongressmedicalnursing-052.

Повний текст джерела

Анотація:

Post-COVID-19 syndrome, also known as long COVID, refers to the persistence of physical and psychological symptoms after the acute phase of SARS-CoV-2 infection. The most common clinical manifestations include chronic fatigue, respiratory difficulties, cognitive changes and sleep disorders, significantly impacting the quality of life of patients. This study provides a comprehensive review of the main clinical manifestations, diagnostic methods and currently recommended therapeutic approaches. The management of post-COVID-19 syndrome involves a multidisciplinary approach that integrates physical rehabilitation, psychological support and drug therapies, with the aim of promoting gradual recovery and minimizing long-term health impacts on affected individuals.

Стилі APA, Harvard, Vancouver, ISO та ін.

Bailey, J., R. Mylvaganam, S. R. Russell, K. Arkin, J. Karon, C. Davidson, J. I. Sznajder, G. S. Budinger, M. A. Sala, and NU Comprehensive COVID Center Investigators. "Computed Tomography Scan Abnormalities in Patients with Post-Acute COVID Syndrome." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3836.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Malagutti, Beatriz Cocato, Lucas da Silva Oliveira, Matheus Spilari, Victoria Lot Avezum Mestriner, and Helen Maia Tavares de Andrade. "Stiff Person syndrome and lumbosacral plexopathy post COVID-19." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.537.

Повний текст джерела

Анотація:

Introduction: Coronavirus diasease 2019 (COVID-19) has been associated with inflammatory, ischemic and autoimmune neurological complications. We report a case of Stiff Person Syndrome (SPS) as an autoimmune neurological complication in COVID-19, an association still rare in the literature. Case report: A 45-year-old woman, presented with back pain of strong intensity with irradiation to the left lower limb, associated with painful muscle contracture and weakness in the same limb with progressive worsening in two days. Neurological examination revealed strength grade II, hyporeflexia, tactile and vibratory hypoesthesia, and paresthesia of the left lower limb, with increased tonus and impossibility to bend the left knee. She presented with positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction 12 days before the onset of symptoms. cCerebrospinal fluid and lumbosacral magnetic resonance imaging without significant changes, left thigh MRI with nonspecific edema and electroneuromyography compatible with left lumbosacral plexopathy. Stiff Person syndrome and autoimmune lumbosacral plexopathy were hypothesized. The treatment was started with methylprednisolone 1 g/day for five days and immunoglobulin 0.4 g/kg/day for five days with partial improvement. Anti-GAD AC performed, non-reactive. Screening for neoplasms was negative. In evolution, the patient progressed with involvement of the right lower limb, trunk, and upper limbs, respectively, with a fluctuating course and partial and temporary response to human immunoglobulin infusion and methylprednisolone pulse therapy. Conclusion: We report the associated time between SPS and COVID-19. SPS is a rare autoimmune disease related to anti-GAD AC and other antibodies. The temporal link with infectious agents that may trigger the autoimmune attack is uncommon in the literature, as the diagnosis is usually made years after the onset of symptoms. In this case, the diagnosis was made soon after infection, which allowed us to report another autoimmune neurological complication in COVID-19.

Стилі APA, Harvard, Vancouver, ISO та ін.

Pocevski, Božidar, Predrag Pocevski, and Marija Pocevski. "Health and social aspects of corona virus disease 2019 pandemic and post-COVID society." In Proceedings of the International Congress Public Health - Achievements and Challenges, 180. Institute of Public Health of Serbia "Dr Milan Jovanović Batut", 2024. http://dx.doi.org/10.5937/batutphco24132p.

Повний текст джерела

Анотація:

It was proven so far, that Severe Acute Respiratory Syndrome induced by Corona Virus 2 (SARSCoV-2) is highly pathogenic virus, which spread rapidly. The spectrum of COVID-19 ranges from asymptomatic infection to severe respiratory failure. COVID-19 caused by SARS-CoV-2 is characterized primary as pulmonary disease. After three years of pandemic and several variants of corona viruses, in scientific circles and, more significant, in practice it turned out that SARS-CoV-2 shows neurological and cardiovascular manifestations. In practice we are facing with post-covid and long-covid symptoms. There are dozens of symptoms which follows acute COVID-19: confusion, stroke, neuromuscular disorders, depression, headache, fatigue, sensory disturbance (anosmia and ageusia), weakness, cognitive dysfunction. Central nervous system manifestations include dizziness, headache, acute cerebrovascular disease, impaired consciousness, transverse myelitis, acute haemorrhagic necrotizing encephalopathy, encephalopathy, encephalitis, epilepsy, ataxia. Peripheral nervous system manifestations include hypogeusia, hyposmia, neuralgia, Guillain Barre syndrome, Miller Fisher syndrome, skeletal muscle injuries. Cardiovascular manifestations include myocardial injury, acute coronary syndrome, heart failure, arrhythmia, coagulopathy, myocarditis. So, in addition, in post-COVID era primary health care practitioners will be challenged how to differentiate patients with primary neurological and cardiovascular problems and those with neurological and cardiovascular complications after SARS-CoV-2 infection. Post-COVID era captures social aspects as well as health public dimensions. We live in world which gives us opportunity to travel freely, but this pandemic showed us that borders can be, and must be closed, especially in unity such as EU. Disintegration or social, interpersonal isolation made us think about how much we were already separated. On television there were many people who used term social distancing, not knowing that term represent psychological condition. In the end, after all these historical turbulences, we will divide world history as one commentator said: B.C. and A.C. - the World Before Corona and After Corona.

Стилі APA, Harvard, Vancouver, ISO та ін.

Delgado, D., and M. Gomez. "Post-Covid-19 Guillain-Barre Syndrome Masked as Acute Congestive Heart Failure Exacerbation." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5620.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Silva, Luciana Maria Campos e., Suelen Darlane Vieira, Ana Catarini Lopes Baltazar, Ana Luiza Soares Henriques de Almeida, Rafael Felipe Silva Rodrigues, Isabela Guedes, Amanda Mansur Rosa, and Maíssa Ferreira Diniz. "Neurocognitive impairment postCOVID-19: a review." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.125.

Повний текст джерела

Анотація:

Background: COVID-19 is an infectious disease caused by SARS-CoV-2, a neurotropic virus. Although its main manifestations are respiratory, neurological complaints associated with COVID-19 are growing. Important cognitive impairments have been shown during and after the acute illness. Objectives: To review post-COVID-19’s neurocognitive deficits. Design and Setting: Review of the literature. Methods: The PubMed database was used with the descriptors “COVID-19” and “neurocognition”, finding 94 articles. Only articles with participants without previous cognitive or psychiatric disorders were included, 7 review articles and 5 cohort studies being selected. Results: All of the reviewed articles demonstrated cognitive impairment in post-COVID-19 patients, including patients without cognitive complaints. Headache, dysgeusia, diarrhea and use of oxygen during acute COVID were related to lower scores on global cognition tests. Severe Acute Respiratory Syndrome (SARS) was associated with a higher risk of cognitive impairment both at hospital discharge and 1 year after, mainly in working memory, processing speed, executive functions and attention. Post-SARS imaging exams showed atrophy and loss of brain volume. The mechanisms of CNS injury in COVID-19 are not completely understood, but systemic hypoxia, associated with important viremia and the massive release of cytokines, has an important role in a picture of toxic encephalopathy and destruction of nervous tissue. Conclusion: There is evidence of neurocognitive impairments as a result of COVID-19, however studies on the mechanisms of occurrence and severity of deficits are scarce. Further studies are needed to identify predictors and develop prevention strategies.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kooner, H. K., M. Faran, M. J. Mcintosh, A. M. Matheson, P. V. Wyszkiewicz, I. Dhaliwal, M. Abdelrazek, J. M. Nicholson, and G. Parraga. "Sex Differences in CT Airway Measurements and Their Relationship to Post-Acute COVID-19 Syndrome." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6791.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Post acute covid 19 syndrome"

Galán-Arroyo, Carmen, Javier de los Ríos-Calonge, Daniela Peñaloza González, Antonio Castillo-Paredes, and Jorge Rojo-Ramos. Quality of Life of Older Adults with Post-Acute COVID-19 Syndrome: a Scoping Review Protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2023. http://dx.doi.org/10.37766/inplasy2023.4.0057.

Повний текст джерела

Анотація:

Review question / Objective: “How does post-acute COVID-19 syndrome affect health-related quality of life (physical-mental-social functioning) in older adults?”. P – People of older adulthood. C – Quality of Life. C – Post-Acute COVID-19 Syndrome. Eligibility criteria: Studies will be assessed for inclusion in the review according to the following criteria: Study Design: We will only include studies that investigate the impact of Post-Acute COVID-19 Syndrome on Quality of Life in older adults. This includes primary research (peer-reviewed research articles), evidence synthesis (narrative reviews, systematic re-views, scoping reviews, rapid reviews, etc.), conference abstracts, discussion articles, editorials, and thesis. We will not limit the included studies by the sample size of the study. Outcomes: We will include studies examining outcomes under the concept quality of life (physical-mental-social functioning), both quantitatively and qualitatively. Study Population and Additional Characteristics: We will only include studies where the study population meets the MeSH (Medical Subject Headings) "Aged" characteristics: A person 65 years of age or older. We will not limit included studies by their ethnicity, country of origin, economic characteristics, or geographic region. We will limit included studies to those published in English, Spanish and Portuguese.

Стилі APA, Harvard, Vancouver, ISO та ін.

Rojo-Ramos, Jorge, Javier de los Ríos-Calonge, Daniela Peñaloza González, Antonio Castillo-Paredes, and Carmen Galán-Arroyo. Quality of Life of Children and Adolescents with Post-Acute COVID-19 Syndrome: a Scoping Review Protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2023. http://dx.doi.org/10.37766/inplasy2023.4.0049.

Повний текст джерела

Анотація:

Review question / Objective: The aim is to conduct a scoping protocol to identify and map how post-acute COVID-19 syndrome affect the quality of life (physical-mental-social functioning) of children and adolescents. Eligibility criteria: Studies will be assessed for inclusion in the review according to the following criteria: Study Design: We will only include studies that investigate the impact of Post-Acute COVID-19 Syndrome on Quality of Life in children and adolescents. This includes primary research (peer-reviewed research articles), evidence synthesis (narrative reviews, systematic reviews, scoping reviews, rapid reviews, etc.), conference abstracts, discussion articles, editorials, and thesis. We will not limit the included studies by the sample size of the study. Outcomes: We will include studies examining outcomes under the concept quality of life (physical-mental-social functioning), both quantitatively and qualitatively. Study Population and Additional Characteristics: We will only include studies where the study population meets the characteristics of the following MeSH (Medical Subject Headings): - "Child, Preschool": An individual 2 to 5 years old. - "Child": A person 6 to 12 years of age. - "Adolescent": A person 13 to 18 years of age. We will not limit included studies by their ethnicity, country of origin, economic characteristics, or geographic region. We will limit included studies to those published in English, Spanish and Portuguese.

Стилі APA, Harvard, Vancouver, ISO та ін.

Nunes, Isadora, Katia Sá, Mônica Rios, Yossi Zana, and Abrahão Baptista. Non-invasive Brain Stimulation in the Management of COVID-19: Protocol for a Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0033.

Повний текст джерела

Анотація:

Review question / Objective: What is the efficacy or effectiveness of NIBS techniques, specifically repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), transcutaneous auricular vagus nerve stimulation (taVNS), percutaneous auricular vagus nerve stimulation (paVNS), and neck vagus nerve stimulation (nVNS), in the control of outcomes associated with COVID-19 in the acute or post-COVID persistent syndrome? Eligibility criteria: Included clinical studies assessed participants with acute or persistent post-COVID-19 syndrome submitted to NIBS interventions, namely transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), transcranial random noise stimulation (tRNS), transcranial magnetic stimulation (TMS), repetitive transcranial magnetic stimulation (rTMS), theta burst (cTBS or iTBS). Studies that used peripheral and spinal cord stimulation techniques were also included. Those included vagus nerve stimulation (VNS), such as transcutaneous auricular (taVNS), percutaneous auricular (paVNS), transcranial random noise stimulation (tRNS) trans-spinal direct current stimulation (tsDCS) and other peripheral electrical stimulation (PES) techniques. Scientific communication, protocol studies, reviews and non-English papers were excluded.

Стилі APA, Harvard, Vancouver, ISO та ін.

Wang, Xiao, Hong Shen, Yujie Liang, Yixin Wang, Meiqi Zhang, and Hongtao Ma. Effects of physical activity interventions for post-COVID-19 patients: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0036.

Повний текст джерела

Анотація:

Review question / Objective: Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused a huge impact in many countries and has attracted great attention from countries around the world. However, since the outbreak of the COVID-19 pandemic, most attention has focused on containing transmission and addressing the surge of critically ill patients in acute care settings. As we enter the second phase of the pandemic, emphasis must evolve to post care of COVID-19 survivors. A variety of persistent symptoms, such as severe fatigue, shortness of breath, and attention disorder have been reported at several months after the onset of the infection. We urgently need to identify safe and effective COVID-19 rehabilitative strategies. Overwhelming evidence exists that physical activity produces short-, middle- and long-term health benefits that prevent, delay, mitigate and even reverse a large number of metabolic, pulmonary and cardiovascular diseases. The purpose of this study was to evaluate the effects of physical activity interventions for rehabilitation of post-covid-19 patient and provide a reliable method and credible evidence to improve the prognosis of post-COVID-19 patients via systematic review and meta-analysis.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kintz, Erica, Erin Lewis, and Victoria Cohen. Qualitative assessment of the risk of SARS-CoV-2 to human health through food exposures to deer in the UK. Food Standards Agency, March 2023. http://dx.doi.org/10.46756/sci.fsa.jip603.

Повний текст джерела

Анотація:

SARS-CoV-2, the coronavirus responsible for the infectious disease COVID-19 (Gorbalenya et al 2020 (Opens in a new window)), was first detected in the human population in December 2019 (Zhu et al 2020 (Opens in a new window)). It has since spread to become a global pandemic. Previously, two other novel coronaviruses caused illness in the human population. The first, SARS-CoV (for Severe Acute Respiratory Syndrome) was recognised as a new illness in 2004 and the second, MERS-CoV (for Middle East respiratory syndrome) in 2012 (de Wit et al. 2016). These previous coronavirus outbreaks in humans occurred after bat coronaviruses passed through intermediate hosts (civet cats and camels, respectively) and then transmitted to infect humans (de Wit et al. 2016). SARS-CoV-2 infections in companion animals such as dogs, cats and ferrets and also in captive or farmed animals such as tigers and mink have been observed, likely as spill over events from contact with infected humans (WOAH 2022). There is now a large body of evidence from the United States that SARS-CoV-2 is capable of infecting white-tailed deer and that it can then spread further in the deer population (details in “What is the risk of SARS-CoV-2 being introduced into the cervid population in Great Britain?” (Defra, 2022). Assuming a worst-case scenario where SARS-CoV-2 is circulating within the UK deer population, this risk assessment was performed to determine whether handling and/or consuming UK-produced deer meat and/or offal may pose a risk of contracting SARS-CoV-2 in humans.

Стилі APA, Harvard, Vancouver, ISO та ін.

Jara Donoso, Angel, Nathacha Garces, Claudio Farías-Valenzuela, Paloma Ferrero-Hernandez, Gerson Ferrari, and Antonio Castillo-Paredes. Effects of aerobic training on respiratory capacity in patients with Post-Covid 19 syndrome. A systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2023. http://dx.doi.org/10.37766/inplasy2023.6.0093.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

F, Verdugo-Paiva, Izcovich A, Ragusa M, and Rada G. Lopinavir/ritonavir for COVID-19: A living systematic review. Epistemonikos Interactive Evidence Synthesis, January 2024. http://dx.doi.org/10.30846/ies.4f3c02f030.v1.

Повний текст джерела

Анотація:

Objective Provide a timely, rigorous, and continuously updated summary of the evidence on the role of lopinavir/ritonavir in the treatment of patients with COVID-19. Methods We conducted searches in the special L.OVE (Living OVerview of Evidence) platform for COVID-19, a system that performs regular searches in PubMed, Embase, CENTRAL, and other 33 sources. We searched for randomized trials and non-randomized studies evaluating the effect of lopinavir/ritonavir versus placebo or no treatment in patients with COVID-19. Two reviewers independently evaluated potentially eligible studies, according to predefined selection criteria, and extracted data using a predesigned standardized form. We performed meta-analyses using randomeffect models and assessed overall certainty in evidence using the GRADE approach. A living, web-based version of this review will be openly available during the COVID-19 pandemic. Results Our search strategy yielded 862 references. Finally, we identified 12 studies, including two randomized trials, evaluating lopinavir/ritonavir, in addition to standard care versus standard care alone in 250 adult inpatients with COVID-19. The evidence from randomized trials shows lopinavir/ritonavir may reduce mortality (relative risk: 0.77; 95% confidence interval: 0.45 to 1.3; low certainty evidence), but the anticipated magnitude of the absolute reduction in mortality, varies across different risk groups. Lopinavir/ritonavir also had a slight reduction in the risk of requiring invasive mechanical ventilation, developing respiratory failure, or acute respiratory distress syndrome. However, it did not lead to any difference in the duration of hospitalization and may lead to an increase in the number of total adverse effects. The overall certainty of the evidence was low or very low. Conclusions For severe and critical patients with COVID-19, lopinavir/ritonavir might play a role in improving outcomes, but the available evidence is still limited. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon Keywords COVID-19, Severe acute respiratory syndrome coronavirus 2, Coronavirus Infections, Systematic review, Lopinavir, Lopinavir/ritonavir, Antivirals

Стилі APA, Harvard, Vancouver, ISO та ін.

Kang, Hanyujie, Nuer Subi, and Zhaohui Tong. Effect of prolonged prone positioning in intubated COVID-19 patients with acute respiratory distress syndrome: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2023. http://dx.doi.org/10.37766/inplasy2023.9.0072.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Şeker, Muzaffer, Ali Özer, Zekeriya Tosun, Cem Korkut, and Mürsel Doğrul, eds. COVID-19 Küresel Salgın Değerlendirme Raporu. Türkiye Bilimler Akademisi, June 2020. http://dx.doi.org/10.53478/tuba.2020.118.

Повний текст джерела

Анотація:

"In late December 2019, a large number of patients with unknown causes of pneumonia were reported by press from a seafood market in Wuhan, Hubei province, China. This coronavirus was originally named the 2019 new coronavirus (2019-nCoV) by the World Health Organization (WHO) on January 12, 2020. The Coronavirus Working Group (CSG) of the WHO and Internati- onal Committee proposed to call the new virus SARS-CoV-2 on February 11, 2020. As a result of the samples taken from the patient, the whole genome sequence of the SARS-CoV-2 was isolated on January 7, 2020, by Chinese scientists in a short time. WHO announced on Febru- ary 11, 2020; that “COVID-19” will become the official name of the disease. Tedros Adhanom Ghebreyesus, director of the WHO, said the epidemic meant “ko”, “corona”, “vi” for “virus” and “d” for “disease” as first described on December 31, 2019. Such a name has been preferred to avoid stigmatizing a particular region, animal species or human. The infection, which started to spread first in China and then in nearby countries, spread to most countries later on. The epidemic soon reached an international dimension, affecting the whole world. As a result, the WHO considered COVID-19 as an international public health problem and declared it as a pandemic on January 30, 2020. In humans, coronaviruses cause some cases of colds and respiratory infections that can be fatal, such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus disease 2019 (COVID-19). In recent years, new viral infections have been detected periodically in various countries. The first epidemic; was observed in 2002-2003 as a result of the crossing of a new coronavirus from bat origin to humans through palm civet cats in Guangdong Province, China. This virus, called SARS, affected a total of 8422 people in China and caused 916 deaths (11% mortality, however different rates are given in different literatures). The second epidemic event occurred approximately 10 years later. In 2012, the MERS coronavirus (MERS-CoV) emerged from bat origin through a dromedary camel in Saudi Arabia. It affected a total of 2494 people and caused 858 deaths (mortality rate of 34%). WHO has declared it as a pandemic after the outbreak and scientists are doing great efforts to identify the characterization of the new coronavirus and to develop antiviral therapies and vaccines. Clinical studies and vaccination studies are still ongo- ing fastly. Also, the pathogenesis of the virus is still not fully known, and new studies are needed in this regard. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2. The most appropriate prophylactic regimen for patients under observa- tion due to COVID-19 related disease is unknown. For this reason, treatment protocols should be planned by following the current guidelines. This study consists of evaluating the opinions about the history of pandemics associated with COVID-19, related definitions and the projects being carried out with the compilation of avai- lable resources, the development stages of the pandemic and the projection of postpandemic interaction."

Стилі APA, Harvard, Vancouver, ISO та ін.

Flagg, Lee Anne. Guidance for Certifying Deaths Due to Coronavirus Disease 2019 (COVID–19): Expanded in February 2023 to Include Guidance for Certifying Deaths Due to Post-acute Sequelae of COVID-19. National Center for Health Statistics (U.S.), February 2023. http://dx.doi.org/10.15620/cdc:124588.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!